Covered recipient · General Payments record
MOHAMMED M MILHEM
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$53.18
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $53.18 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $53.18 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MOHAMMED M MILHEM
NPI 1558429100 · CMS profile ID 806076
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
IOWA CITY, IA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $53.18 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $53.18 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242511626 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $9,472.81 | 4 |
| PY2025 | Principal investigator | $581,246.58 | 77 |
| PY2024 | Principal investigator | $999,952.01 | 109 |
| PY2023 | Recipient | $1,270.00 | 2 |
| PY2023 | Principal investigator | $827,610.63 | 137 |
| PY2022 | Principal investigator | $1,233,503.31 | 110 |
| PY2021 | Principal investigator | $751,345.38 | 31 |
| PY2020 | Principal investigator | $896,218.13 | 99 |
| PY2019 | Recipient | $476.00 | 1 |
| PY2019 | Principal investigator | $1,105,673.41 | 103 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
109 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $43,197.49 | 12/31/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group | No dispute reported | 06/30/2026 | 1136410738 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,143.78 | 12/31/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group | No dispute reported | 06/30/2026 | 1136410742 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,049.28 | 12/31/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 | No dispute reported | 06/30/2026 | 1136414176 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $137,051.33 | 12/31/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with Pembrolizumab Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma KEYVIBE-010 | No dispute reported | 06/30/2026 | 1136428492 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $358,094.10 | 12/31/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 | No dispute reported | 06/30/2026 | 1136437589 |
| Principal investigator 3 | Merck Sharp & Dohme LLC | $30,192.20 | 12/20/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | No dispute reported | 06/30/2026 | 1136411266 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38,220.18 | 12/20/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $274.05 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,877.20 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409529 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,226.48 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,039.30 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,159.00 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,890.00 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $612.36 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,047.50 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,505.70 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,557.36 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.59 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,050.00 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $675.00 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409553 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $346.50 | 12/02/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409555 |
| Principal investigator 1 | Immunocore Limited | $326.71 | 09/19/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma | No dispute reported | 06/30/2026 | 1103129703 |
| Principal investigator 1 | Genentech, Inc. | $2,000.00 | 09/10/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1133376352 |
| Principal investigator 1 | Genentech, Inc. | $725.00 | 09/10/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1133376356 |
| Principal investigator 1 | Genentech, Inc. | $26,736.00 | 09/10/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1133376358 |
| Principal investigator 1 | Genentech, Inc. | $2,250.00 | 09/10/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1133376360 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,106.28 | 09/09/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409495 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,106.28 | 09/09/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409497 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $2,500.00 | 09/06/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520870 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $725.00 | 09/06/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520872 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $500.00 | 09/06/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520874 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $4,150.00 | 09/06/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520876 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,106.00 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) | No dispute reported | 06/30/2026 | 1146134509 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,727.00 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) | No dispute reported | 06/30/2026 | 1146134511 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $600.00 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) | No dispute reported | 06/30/2026 | 1146134513 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $2,500.00 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) | No dispute reported | 06/30/2026 | 1146134515 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,034.00 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) | No dispute reported | 06/30/2026 | 1146134517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,106.28 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409481 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $274.05 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409483 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $54.81 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409485 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,106.28 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409487 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,106.28 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409489 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,106.28 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409491 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $505.38 | 09/04/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409493 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,843.58 | 08/31/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | A Study of DF6002 Alone and in Combination With Nivolumab | No dispute reported | 06/30/2026 | 1123473669 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $16,248.18 | 08/21/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group | No dispute reported | 06/30/2026 | 1136410747 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57,141.95 | 08/05/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409479 |
| Principal investigator 1 | PFIZER INC. | $1,200.00 | 07/10/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1130948630 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $2,631.91 | 06/25/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131056195 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,086.56 | 06/10/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,086.56 | 06/10/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409461 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,086.56 | 06/10/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,721.16 | 06/10/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $274.05 | 06/10/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409467 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $124.81 | 06/10/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409469 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $14,254.50 | 06/07/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131046920 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $1,460.00 | 06/07/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131046926 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $3,489.88 | 06/07/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131048047 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $725.00 | 06/07/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131048086 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $1,100.00 | 06/07/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131048093 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $2,250.00 | 06/07/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131055713 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $2,500.00 | 06/07/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131056201 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,677.56 | 05/17/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409445 |
| Principal investigator 1 | PFIZER INC. | $600.00 | 05/08/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1130947516 |
| Principal investigator 1 | Genentech, Inc. | $689.00 | 05/07/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1133376346 |
| Principal investigator 1 | Genentech, Inc. | $10,348.00 | 05/07/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1133376350 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 04/29/2024 | Non-covered Recipient Entity University Of Iowa | MRD Monotherapy, combination of VSV-GP w/ antiPD1 | No dispute reported | 06/30/2026 | 1101072227 |
| Principal investigator 1 | Genentech, Inc. | $4,230.00 | 04/25/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1133376348 |
| Principal investigator 1 | PFIZER INC. | $54,941.00 | 04/24/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1130947522 |
| Principal investigator 1 | PFIZER INC. | $1,200.00 | 04/24/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | No dispute reported | 06/30/2026 | 1130948636 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,767.00 | 04/15/2024 | Non-covered Recipient Entity AHS Hospital Corp Atlantic Health System | MRD Monotherapy, combination of VSV-GP w/ antiPD1 | No dispute reported | 06/30/2026 | 1101072229 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,725.00 | 04/03/2024 | Non-covered Recipient Entity State University Of Iowa Ste 168c | MRD Monotherapy, combination of VSV-GP w/ antiPD1 | No dispute reported | 06/30/2026 | 1101072231 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $1,580.80 | 03/15/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131055016 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $1,650.00 | 03/15/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131055027 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $5,076.50 | 03/15/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131055550 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $809.28 | 03/15/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131055920 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $2,056.60 | 03/15/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131056378 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $418.95 | 03/06/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409427 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $329.17 | 03/06/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,575.00 | 03/06/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409431 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,575.00 | 03/06/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1082409433 |
| Principal investigator 1 | TRILLIUM THERAPEUTICS USA, LLC | $1,650.00 | 02/26/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A PHASE III STUDY OF TTI621 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH UNRESECTABLE OR METASTATIC HIGHGRADE LEIOMYOSARCOMA | No dispute reported | 06/30/2026 | 1131056382 |
| Principal investigator 1 | Genentech, Inc. | $4,577.00 | 02/06/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1133376344 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,465.00 | 01/29/2024 | Non-covered Recipient Entity UNIVERSITY OF IOWA | LONG TERM FOLLOW-UP OF PARTICIPANTS EXPOSED TO GSK3377794 (NY-ESO-1C25 | No dispute reported | 06/30/2026 | 1127521123 |
| Principal investigator 1 | Immunocore Limited | $653.42 | 01/29/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma | No dispute reported | 06/30/2026 | 1103129643 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,000.00 | 01/26/2024 | Non-covered Recipient Entity THE UNIVERSITY OF IOWA | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN | No dispute reported | 06/30/2026 | 1127521125 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,000.00 | 01/26/2024 | Non-covered Recipient Entity THE UNIVERSITY OF IOWA | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN | No dispute reported | 06/30/2026 | 1127521127 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $700.00 | 01/26/2024 | Non-covered Recipient Entity THE UNIVERSITY OF IOWA | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN | No dispute reported | 06/30/2026 | 1127521129 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 01/26/2024 | Non-covered Recipient Entity THE UNIVERSITY OF IOWA | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN | No dispute reported | 06/30/2026 | 1127521131 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,800.00 | 01/26/2024 | Non-covered Recipient Entity THE UNIVERSITY OF IOWA | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN | No dispute reported | 06/30/2026 | 1127521133 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $3,000.00 | 01/19/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) | No dispute reported | 06/30/2026 | 1146134503 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $10,000.00 | 01/19/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) | No dispute reported | 06/30/2026 | 1146134505 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $750.00 | 01/19/2024 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) | No dispute reported | 06/30/2026 | 1146134507 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $550.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520816 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $750.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520818 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $500.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520822 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $750.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520840 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $550.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520848 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $750.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520850 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $750.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520852 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $750.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520854 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $750.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520856 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $750.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520858 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $750.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520860 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $750.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520862 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $750.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520864 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $500.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520866 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $750.00 | 01/05/2024 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | ADCT-601-102 | No dispute reported | 06/30/2026 | 1126520868 |